Portal de Periódicos da CAPES

Low-Frequency Nevirapine (NVP)–Resistant HIV-1 Variants Are Not Associated With Failure of Antiretroviral Therapy in Women Without Prior Exposure to Single-Dose NVP

2014; Oxford University Press; Volume: 209; Issue: 5 Linguagem: Inglês

10.1093/infdis/jit635

1537-6613

Valerie F. Boltz, Yajing Bao, Shahin Lockman, Elias K. Halvas, Mary F. Kearney, James McIntyre, Robert T. Schooley, Michael D. Hughes, John M. Coffin, John W. Mellors, Beth Zwickl, C. Kityo Mutuluuza, Christine Kaseba, Charles C. Maponga, Heather Watts, Daniel R. Kuritzkes, Thomas Campbell, Lynn Kidd-Freeman, Monica Carten, Jane Hitti, Mary Marovich, Peter Mugyenyi, Sandra Rwambuya, Ian Sanne, Beverly Putnam, Cheryl Marcus, Carolyn Wester, Robin DiFrancesco, Elias K. Halvas, Annie Beddison, Sandra Nusinoff Lehrman, Francesca Aweeka, Betty J. Dong, Peter Ndhleni Ziba, Michael S. Saag, William C. Holmes, Scott M. Hammer,

HIV/AIDS Research and Interventions

Background. Low-frequency nevirapine (NVP)–resistant variants have been associated with virologic failure (VF) of initial NVP-based combination antiretroviral therapy (cART) in women with prior exposure to single-dose NVP (sdNVP). We investigated whether a similar association exists in women without prior sdNVP exposure.